polyICLC
Phase 2Small molecule
polyICLC is one of 45 small molecule programs targeting Melanoma. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
191 competitors in Melanoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Mekinist
NovartisPhase 3
Cotellic
RochePhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Taxol
TevaPhase 3
Mektovi
PfizerPhase 3
Tecentriq
RochePhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Melanoma3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for polyICLC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCraig L Slingluff, Jr